Frank Ubags

Chief Executive Officer

Frank Ubags joined CEVEC in October 2014 as Chief Operating Officer and Managing Director. He has over 35 years of leadership experience in renowned companies. He has successfully executed major financing transactions, turn around projects, and initiated and executed major M&A transactions, in both acquiring and selling companies. Frank joined the life sciences industry in 1997 as CFO of Rhein Biotech, where he led the 1999 IPO and was responsible for the transformation of Rhein Biotech into a vaccines company followed by, two years later, a trade sale to Berna Biotech. In addition, Frank’s experience has included CEO, COO and CFO positions in companies such as the German Rhein Biotech operation, Kiadis Pharma and Scil Proteins. Frank holds several advisory positions in the field of protein production.

Dr. Nicole Faust

Chief Scientific Officer

Dr. Nicole Faust holds a Ph.D. in Molecular and Cell Biology. After a post-doctoral period at the EMBL, Heidelberg, she joined Artemis-Pharmaceuticals GmbH, Cologne in 1999 where she took over responsibility for the Molecular Technology group as Associate Director R&D. In 2004 she started a position with amaxa GmbH, now Lonza Cologne GmbH. As Director R&D she was responsible for developing transfection technologies, for the cell-based assay program, and for establishing and running the cell line development services. She joined CEVEC in May 2011 as VP Development & Services and was appointed Chief Scientific Officer in 2014.

Dr. Hartmut Tintrup

Chief Business Officer

Dr. Hartmut Tintrup served previously as VP Business Development & Licensing at CEVEC and holds a Ph.D. in Neurochemistry from Frankfurt University, Germany. He spent 16 years in various positions of increasing responsibility at leading Biotech Companies in the US and Germany. Prior to joining CEVEC he held management positions at amaxa AG and Lonza in Industrial Sales, Export and Tactical Marketing. Hartmut joined CEVEC in 2010 and was appointed Chief Business Officer in 2014.